Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtideBonaventura Clotet, Jonathan Schapiro, François Raffi et al.|AIDS|2004Cited by 72
Antiretroviral Therapy for HIV-2 Infected PatientsN A Smith, Judith Breuer, Aklak Choudhury et al.|Journal of Infection|2001Cited by 56
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M. Gatell, Nadine Ktorza, Lambert Assoumou et al.|Clinical Infectious Diseases|2018Cited by 48
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna Gonzalez‐Cordón, Juergen Rockstroh, Lambert Assoumou et al.|Journal of Antimicrobial Chemotherapy|2021Cited by 27
Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of TherapyOle Kirk, Jens Lundgren, Court Pedersen et al.|Antiviral Therapy|2002Cited by 22